KPCM
STAB

Kings Point Capital Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Kings Point Capital Management’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-500
Closed -$12K – 292
2013
Q4 		$12K Hold
500
– – ﹤0.01% 248
2013
Q3 		$16K Hold
500
– – 0.01% 235
2013
Q2 		$16K Buy
+500
New +$17.2K 0.01% 243

Other funds holding STAB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Kings Point Capital Management's STAB Position: Q1 2014 in Review

Kings Point Capital Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2014, closing a stake of 500 shares — an estimated $12K sold.

Kings Point Capital Management first reported a position in STAB in Q2 2013 and held it in 3 quarters. The position peaked at $16K in Q3 2013. 35 funds tracked by Wall St. Rank hold STAB as of Q1 2014.

  • Kings Point Capital Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Kings Point Capital Management sold 500 Statera Biopharma, Inc. Common Stock shares in Q1 2014, an estimated $12K.
  • Kings Point Capital Management first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 3 quarters.
  • Kings Point Capital Management's Statera Biopharma, Inc. Common Stock position peaked at $16K in Q3 2013.
  • 35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2014.

Based on Kings Point Capital Management's 13F filing for Q1 2014, filed 12 May 2014.